The CDC recommended the Pfizer and Moderna COVID-19 vaccines to all eligible persons after a study found the vaccines effective in real-world conditions.
Officials have tried to scare us into thinking we cannot go back to normal because of COVID variants and people still get symptomatic infections.
The study examined vaccinated and non-vaccinated health care personnel, first responders, and other frontline workers. In all, 3,950 in eight locations received a weekly COVID test from Dec. 14 to March 13.
The CDC discovered only three infections of the 2,479 fully vaccinated participants. The tests found eight infections of the 477 people who only had one dose.
161 people of the 944 unvaccinated had infections.
“Prospective cohorts of health care personnel, first responders, and other essential and frontline workers over 13 weeks in eight U.S. locations confirmed that authorized mRNA COVID-19 vaccines (Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273) are highly effective in real-world conditions,” the CDC concluded. “Vaccine effectiveness of full immunization with two doses of mRNA vaccines was 90% (95% CI = 68%–97%) against RT-PCR–confirmed SARS-CoV-2 infection.”
The participants are the best part of this study. These people help patients with the infection. They are constantly exposed. If they have these results imagine the results for the non-frontline workers:
These findings are consistent with those from the mRNA vaccines’ Phase III trials (1,2) and recent observational studies of the mRNA vaccine effectiveness against severe COVID-19 (3). The findings complement and expand upon these preceding reports by demonstrating that the vaccines can also reduce the risk for infection regardless of COVID-19–associated illness symptom status (4,5). Reducing the risk for transmissible infection, which can occur among persons with asymptomatic infection or among persons several days before symptoms onset (6), is especially important among health care personnel, first responders, and other essential and frontline workers given their potential to transmit the virus through frequent close contact with patients and the public.Partial immunization (≥14 days after first dose but before second dose) provided preventive benefits with vaccine effectiveness of 80%. This finding is similar to an analysis of Phase III trial results (1,2,7) and two other recent estimates of vaccine effectiveness for partial immunization with Pfizer-BioNTech vaccine among health care personnel, including a vaccine effectiveness (≥21 days after first dose) of 72% (95% CI = 58%–86%) against PCR-confirmed infection identified by routine testing in the United Kingdom (4) and a vaccine effectiveness (>14 days after first dose) of 60% (95% CI = 38%–74%) against PCR-confirmed infection identified by records review in Israel (5). This finding is also consistent with early descriptive findings of SARS-CoV-2 employee and clinical testing results by mRNA vaccination status in the United States (8,9).
CLICK HERE FOR FULL VERSION OF THIS STORY